Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohammed Eslam

Showing results (51-60 of 224) with videos related to

Pageof 23
Sort By:
Hepatitis Monthly|February 8, 2012
Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infectionMahmoud Aboelneen Khattab, Mohammed Eslam, Seyed Moayed Alavian
Hepatology International|August 28, 2024
Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLDMingqian Jiang, Ziyan Pan, Jacob George, et al.
Hormones (Athens, Greece)|August 28, 2022
Correction to: Detangling the interrelations between MAFLD, insulin resistance, and key hormonesShreya C Pal, Mohammed Eslam, Nahum Mendez-Sanchez
Hepatology International|March 1, 2026
Assessing pricing and affordability of HBV treatment in JapanMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Journal of Hepatology|December 19, 2024
Transitions in the nomenclatures for fatty liver diseaseMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Clinical and Molecular Hepatology|July 22, 2024
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis"Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Annals of Hepatology|September 24, 2025
Drug pricing for hepatitis B and C in Australia and JapanMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Hepatology International|October 16, 2024
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver researchMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
The Lancet. Gastroenterology & Hepatology|May 16, 2020
Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic healthMohammed Eslam, Jian-Gao Fan, Nahum Mendez-Sanchez
Hepatology International|April 2, 2025
Reply to "Metabolic (dysfunction)-associated fatty liver disease metrics and contributions: Correspondence"Maito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Pageof 23

Showing results (51-60 of 224) with videos related to

Sort By:
Pageof 23
Hepatitis Monthly|February 8, 2012
Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infectionMahmoud Aboelneen Khattab, Mohammed Eslam, Seyed Moayed Alavian
Hepatology International|August 28, 2024
Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLDMingqian Jiang, Ziyan Pan, Jacob George, et al.
Hormones (Athens, Greece)|August 28, 2022
Correction to: Detangling the interrelations between MAFLD, insulin resistance, and key hormonesShreya C Pal, Mohammed Eslam, Nahum Mendez-Sanchez
Hepatology International|March 1, 2026
Assessing pricing and affordability of HBV treatment in JapanMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Journal of Hepatology|December 19, 2024
Transitions in the nomenclatures for fatty liver diseaseMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Clinical and Molecular Hepatology|July 22, 2024
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis"Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Annals of Hepatology|September 24, 2025
Drug pricing for hepatitis B and C in Australia and JapanMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Hepatology International|October 16, 2024
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver researchMaito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
The Lancet. Gastroenterology & Hepatology|May 16, 2020
Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic healthMohammed Eslam, Jian-Gao Fan, Nahum Mendez-Sanchez
Hepatology International|April 2, 2025
Reply to "Metabolic (dysfunction)-associated fatty liver disease metrics and contributions: Correspondence"Maito Suoh, Saeed Esmaili, Mohammed Eslam, et al.
Pageof 23